Ongoing Clinical Trials for Paraneoplastic Neurological Syndrome
Currently, there is 1 ongoing clinical trial investigating new treatment approaches for paraneoplastic neurological syndrome. This trial is focused on early immunotherapy using a combination of medications to help manage symptoms and potentially improve outcomes for patients with this rare immune-related nerve condition.
Clinical trial locations
Study on Early Immunotherapy with Human Normal Immunoglobulin, Cyclophosphamide, and Methylprednisolone for Patients with Anti-Hu Paraneoplastic Sensory Neuropathy
This clinical trial is investigating a rare condition called paraneoplastic sensory neuropathy with anti-Hu antibodies. In this disorder, the body’s immune system mistakenly attacks its own nerve cells, which is often associated with cancer. The study focuses on whether early treatment with a combination of three medications can help improve symptoms and nerve function.
Main inclusion criteria:
- Adults aged 18 years or older
- Diagnosis of anti-Hu antibody paraneoplastic sensory neuropathy with positive anti-Hu antibodies detected in blood or cerebrospinal fluid
- Recent onset of neurological symptoms (less than 3 months ago)
- Presence of sensory neuropathy and coordination problems (sensitive ataxia) that do not severely affect daily functioning
- Able to manage daily activities independently (Modified Rankin Score of 2 or 3)
- Able to provide informed consent and registered with a social security scheme
Main exclusion criteria:
- Patients who do not have paraneoplastic sensory neuropathy with anti-Hu antibodies
- Patients outside the specified age range for the study
- Vulnerable populations who may need special protection or care, such as those unable to make decisions for themselves
Focus and goal of the trial:
The main goal of this study is to evaluate whether early treatment with a combination of immunotherapy medications can improve symptoms and nerve function in patients with this condition. Participants will be monitored over a three-month period to track improvements in nerve function, overall health, and any side effects from treatment. The trial uses various assessment scales to measure clinical improvement, including coordination, disability level, and overall nerve function. Follow-up assessments continue at both 3 and 6 months to determine the effectiveness of the treatment approach.
Investigational drugs:
The trial tests three medications given through intravenous infusion:
- Intravenous Immunoglobulin: A mixture of antibodies that helps boost and modulate the immune system, potentially reducing inflammation and autoimmune activity
- Cyclophosphamide: An immunosuppressant medication that works by reducing the activity of immune cells that may be attacking the body’s own tissues
- Methylprednisolone: A corticosteroid that reduces inflammation and suppresses immune responses by mimicking natural hormones that decrease immune activity
Throughout the study, participants receive regular monitoring to ensure safety and to evaluate how well they tolerate the treatment. The trial tracks any improvements in symptoms such as pain, numbness, tingling, and difficulty with movement and coordination.
Summary
Currently, there is one active clinical trial for paraneoplastic neurological syndrome, specifically focusing on patients with anti-Hu antibody paraneoplastic sensory neuropathy. This trial is being conducted in France and represents an important research effort for this rare condition. The study investigates an early immunotherapy approach using a triple-medication combination of intravenous immunoglobulin, cyclophosphamide, and methylprednisolone. The focus on early intervention within three months of symptom onset reflects an effort to determine whether prompt treatment can make a meaningful difference for patients with this challenging immune-related nerve disorder. The trial aims to provide valuable information about both the effectiveness and tolerability of this treatment strategy.
